Preparation method and application of exosome-enriched scaffold

Through the thermal modification and pH-dependent charge characteristics of the chitosan-sponge composite porous scaffold, the problem of rapid removal and separation of exosomes in the body is solved, efficient enrichment and preservation of exosomes is achieved, and wound healing process is promoted. , significantly improves the biological activity and clinical application potential of exosomes.

CN117618658BActive Publication Date: 2024-11-12GENERAL HOSPITAL OF PLA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311678517.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-08
Publication Date
2024-11-12
Estimated Expiration
2043-12-08

AI Technical Summary

Technical Problem

In the prior art, the methods for rapid removal and separation of exosomes in vivo are complex and costly, which makes their clinical application challenging and their biological activity decrease, making it difficult to effectively promote wound healing.

Method used

The chitosan-sponge composite porous scaffold was used for constant temperature drying and heat modification, and an acid-insoluble scaffold was prepared, and the exosomes were automatically captured and released at different pH values ​​through the scaffold, which simplified the enrichment and preservation process of exosomes. .

Benefits of technology

It achieves efficient enrichment and preservation of exosomes, promotes cell proliferation, migration, angiogenesis and inflammation inhibition, significantly accelerates the wound healing process, and the scaffold can store exosomes for a long time at room temperature to maintain molecular integrity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117618658B_ABST
    Figure CN117618658B_ABST
Patent Text Reader

Abstract

The present invention discloses a method for preparing an exosome-enriched scaffold and its application. The present invention discloses a method for preparing an exosome-enriched scaffold and provides an exosome-enriched scaffold prepared according to the preparation method. The present invention also provides a method for enriching exosomes and a method for storing and transporting exosomes. The present invention also provides an application of the above-mentioned preparation method, enrichment method and scaffold product in the preparation of products, and the prepared products may include wound repair, brain injury treatment, tissue regeneration, tissue reconstruction, inflammation inhibition, immune regulation, paracrine regulation, hair follicle regeneration, promotion of cell proliferation, promotion of cell migration, promotion of cell tubular structure formation, and promotion of vascularization, and have extremely broad market application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology and relates to a preparation method of an exosome-enriched scaffold and an application thereof. Background Art

[0002] Regenerative repair of skin wounds remains a challenge. Wound healing is a complex biological process that includes bleeding, inflammation, proliferation, and remodeling, which is affected by various cells, cytokines, and extracellular matrix (ECM). A large number of studies have shown that human umbilical cord mesenchymal stem cells (hUC-MSCs) have the potential to promote tissue repair, including skin, muscle, and bone. The paracrine effect has become the mainstream theory of the biological activity of these cells, which is mediated by exosomes, which are subcellular structures encapsulated by a lipid bilayer membrane, ranging in size from 40nm to 160nm, and released by most cell types. These exosomes are composed of a variety of biomolecules, such as proteins, lipids, DNA, mRNA, and miRNA, and are essential for cell differentiation, proliferation, angiogenesis, stress response, and immune signaling. Increasing evidence shows that mesenchymal stem cell-derived exosomes have the regenerative potential to accelerate wound healing. These exosomes affect recipient cells by inducing epigenetic changes, positively regulating their physiological state, promoting proliferation or inhibiting apoptosis, thereby leading to tissue repair and regeneration. However, their clinical application remains challenging due to the rapid clearance of exosomes in vivo resulting in reduced biological activity and the complex, costly and time-consuming isolation methods. Summary of the invention

[0003] In order to solve the technical problems existing in the prior art, the following technical solutions are provided:

[0004] The present invention provides a method for preparing an exosome-enriched scaffold, the preparation method comprising subjecting a chitosan-sponge composite porous scaffold to constant temperature drying and heat modification for 10 min-30 min, wherein the constant temperature is 160° C.-180° C., to obtain a final product, an acid-insoluble scaffold.

[0005] Furthermore, the preparation method comprises the following steps:

[0006] 1) Dissolve chitosan in weak acid and mix well to make it fully dissolved;

[0007] 2) Freezing at -20°C for 3 hours, and freeze-drying at -80°C for 24 hours to obtain a chitosan-sponge composite porous scaffold;

[0008] 3) The chitosan-sponge composite porous scaffold is subjected to constant temperature drying and heat modification for 10 min to 30 min, wherein the constant temperature is 160° C. to 180° C., to obtain the final product, an acid-insoluble scaffold.

[0009] The term "thermal modification" refers to the process of modifying a composite scaffold using ambient temperature. Specifically, the ambient temperature is a temperature higher than room temperature, and the surface properties of the scaffold are changed after the "thermal modification".

[0010] In some embodiments, the process of the constant temperature drying thermal modification lasts for 10min, 11min, 12min, 13min, 14min, 15min, 16min, 17min, 18min, 19min, 20min, 21min, 22min, 23min, 24min, 25min, 26min, 27min, 28min, 29min, 30min. In some embodiments, the range of the constant temperature includes 160°C, 161°C, 162°C, 163°C, 164°C, 165°C, 166°C, 167°C, 168°C, 169°C, 170°C, 171°C, 172°C, 173°C, 174°C, 175°C, 176°C, 177°C, 178°C, 179°C, 180°C.

[0011] Furthermore, the weak acid in step 1) includes acetic acid, carbonic acid, nitrous acid, and hypochlorous acid.

[0012] Furthermore, in step 1), the weak acid is acetic acid.

[0013] Furthermore, in the step 1), the acetic acid is 1% v / v.

[0014] Furthermore, in step 1), the final concentration of the chitosan solution is 1%-3%.

[0015] In some embodiments, the final concentration of the chitosan solution is 1%, 1.5%, 2%, 2.5%, or 3%.

[0016] Furthermore, the mixing in step 1) includes stirring mixing and shaking mixing, and the mixing time is 3 hours.

[0017] Furthermore, the drying in step 3) includes forced air drying.

[0018] Furthermore, the exosomes include stem cell exosomes.

[0019] Furthermore, the exosomes include mesenchymal stem cell exosomes.

[0020] Furthermore, the exosomes include exosomes produced by bacteria.

[0021] Furthermore, the exosomes include exosomes produced by somatic cells.

[0022] The term "exosome" refers to endocytosis-derived nanovesicles secreted by almost all cell types in the body. Exosomes or exosome-like vesicles include proteins, nucleic acids (especially miRNA) and lipids. In practice, exosomes or exosome-like vesicles can be separated and / or purified according to any suitable method known to those skilled in the art, or a method improved therefrom. In certain specific embodiments, the cells secreting exosomes are stem cells, more specifically, the cells are mesenchymal stem cells. In certain specific embodiments, the cells secreting exosomes are somatic cells. In certain specific embodiments, the cells secreting exosomes are bacteria.

[0023] The term "scaffold" refers to a molecule that can be used to anchor a target payload or any other compound (e.g., ASO) to an EV on the luminal or external surface of an EV (extracellular vesicle, e.g., exosome). In some aspects, the scaffold comprises a synthetic molecule. In some aspects, the scaffold comprises a non-polypeptide portion. In other aspects, the scaffold comprises a lipid, carbohydrate, or protein that is naturally present in an EV. In some aspects, the scaffold comprises a lipid, carbohydrate, or protein that is not naturally present in an EV. Non-limiting examples of other scaffolds that can be used in the embodiments include: aminopeptidase N (CD13); enkephalinase, AKA membrane metalloendopeptidase (MME); ectonucleotide pyrophosphatase / phosphodiesterase family member 1 (ENPP1); neuropilin-1 (NRP1); CD9, CD63, CD81, PDGFR, GPI anchor protein, lactadherin (MFGE8), LAMP2, and LAMP2B.

[0024] The term "chitosan" refers to a linear polysaccharide composed of glucosamine (deacetylated units) and N-acetylglucosamine (acetyl units) randomly distributed and combined through β-(1-4) glycosidic bonds. Chitosan is prepared by deacetylation of chitin. The term "chitosan" refers to chitosan, chitosan derivatives, and mixtures of chitosan and chitosan derivatives.

[0025] The present invention provides an exosome-enriched scaffold prepared according to the aforementioned preparation method.

[0026] In some embodiments, the enrichment refers to the step of collecting the trace elements to be determined from a large amount of the parent substance into a smaller volume, thereby increasing their content to above the lower limit of determination. If the trace substance with a content of less than 0.01% in the sample is below the lower limit of determination of the analytical method, a pre-enrichment method must be used. In a specific embodiment, the enriched target is exosomes.

[0027] The present invention provides a method for enriching exosomes, the method comprising the following steps:

[0028] 1) Mix the exosome solution with MES buffer at a ratio of 1:4, adjust the pH value, then add the exosome enrichment scaffold described above, mix on ice, and obtain exosomes bound to the exosome enrichment scaffold; 2) Use an alkaline solution to wash and release the exosomes on the exosome enrichment scaffold to obtain an exosome enrichment product.

[0029] Furthermore, the pH value includes 5.8-6.2.

[0030] In some specific embodiments, the pH value is adjusted to 5.8, 5.85, 5.9, 5.95, 6.0, 6.05, 6.1, 6.15, or 6.2.

[0031] Furthermore, the mixing time on ice is 30 min, and the mixing method is shaking mixing.

[0032] Further, the alkaline solution includes a solution prepared from sodium phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, ammonium phosphate, ammonium dihydrogen phosphate, and / or diammonium hydrogen phosphate.

[0033] Furthermore, the alkaline solution is a NaHCO3 solution.

[0034] Furthermore, the pH value of the NaHCO3 solution is 8.0-10.6.

[0035] In some embodiments, the pH value of the alkaline solution NaHCO3 solution includes 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.1, 10.2, 10.3, 10.4, 10.5, and 10.6.

[0036] Furthermore, the pH value of the MES buffer solution is 6.0.

[0037] Furthermore, the concentration of the MES buffer is 100 mM.

[0038] Furthermore, the exosome solution also includes a preliminary impurity removal step.

[0039] Furthermore, the preliminary impurity removal step includes: using a filter to remove dead cells and cell debris from the exosome solution.

[0040] Further, the filter includes a filter having a diameter of 0.2 μm.

[0041] The term "filter" refers to a filter that is able to pass exosomes but blocks dead cells or cell debris or other bulky materials during the filtration process.

[0042] Furthermore, the steps of the method for enriching exosomes can be repeated continuously.

[0043] In some embodiments, the method for enriching exosomes can continuously enrich exosomes in the same exosome-containing solution, or can enrich exosomes in multiple exosome solutions from different sources together. In a specific embodiment, the method for enriching exosomes comprises the following steps: 1) using a filter to remove dead cells and cell debris from the exosome solution. 2) mixing the filtered solution with MES buffer (pH=6.0) at a ratio of 1:4, and adjusting the pH value to 5.8-6.2. Then add the T-CS scaffold to the mixture and shake it on ice for 30 minutes. 3) directly use the T-CS bound to the exosomes for animal experiments, analysis, freeze drying, or collection of exosomes released after washing with NaHCO3 (pH=8.0-10.6).

[0044] The term "alkaline solution" means a solution with a pH greater than 7.0 at room temperature, which can also be understood as a solution in which the concentration of hydroxide is greater than the concentration of hydrogen ions. The term "acidic solution" means a solution with a pH less than 7.0 at room temperature, which can also be understood as a solution in which the concentration of hydrogen ions is greater than the concentration of hydroxide.

[0045] The present invention provides a method for preserving and transporting exosomes, wherein the exosomes bound to the exosome enrichment scaffold in step 1) of the aforementioned method for enriching exosomes are freeze-dried as a whole, and then directly transported and / or stored at room temperature.

[0046] Furthermore, the molecular integrity of the exosomes in the freeze-dried state is not impaired during transportation and / or storage at room temperature.

[0047] The term "lyophilization" refers to the "freeze drying" process, which involves converting water from a frozen state to a gaseous state without passing through a liquid state. The freeze drying process removes water from a water-containing material while the material remains frozen. The basic process of freeze drying includes the following steps: freezing, primary drying (sublimation) and secondary drying (desorption). First, the dissolved and / or suspended material is frozen at a low temperature (e.g., -60°C). Slow freezing produces larger crystals, allowing sublimated materials to escape. Some products form glassy materials and may require annealing during the freezing process. Annealing means first lowering the temperature, then raising the temperature, and then lowering the temperature again to lock the ingredients in place and then allow the crystals to grow. The freezing time can range from 1 hour to 24 hours, depending on the application. In step 2 (primary drying), water or diluent is then extracted via vacuum, resulting in a porous, dry "cake". Sublimation occurs under vacuum, and the product temperature is below its critical temperature. This is usually the longest process. At the end of the primary drying cycle, the product will have a moisture content of 3% to 5%. A final drying step (secondary drying) is used to remove the remaining unfrozen water molecules. This process is accomplished by heating the product. Secondary drying can result in a moisture content of about 0.5%.

[0048] The present invention provides a composition prepared by the above-mentioned method for enriching exosomes, wherein the composition comprises an exosome enrichment scaffold and exosomes bound thereto, and / or collected exosomes.

[0049] The term "composition" refers to a composition of enriched exosomes and exosome-enriched scaffolds bound thereto. The physical form of the composition is not limited. For example, the term "composition" encompasses and discloses a powder, wherein each of the listed substances is present in powder form. As another example, the term "composition" also encompasses and discloses a liquid solution, wherein each of the listed substances is present in a soluble form. As another example, the term "composition" also encompasses and discloses an emulsion, wherein the listed substances are present. As another example, the term "composition" also encompasses and discloses a suspension, wherein the listed substances are present.

[0050] The present invention provides application of the aforementioned preparation method in preparing an exosome-enriched scaffold.

[0051] As used herein, the term "about" refers to the usual error range for each value that is readily known to those skilled in the art. Reference herein to "about" a value or parameter includes (and describes) embodiments for that value or parameter per se.

[0052] The present invention provides the aforementioned preparation method, the aforementioned exosome enrichment scaffold, the aforementioned method for enriching exosomes, and the use of the aforementioned composition in preparing a product.

[0053] Furthermore, the products include wound repair products, brain injury treatment products, tissue regeneration products, tissue reconstruction products, inflammation suppression products, immunomodulatory products, paracrine regulation products, hair follicle regeneration products, cell proliferation promotion products, cell migration promotion products, cell tubular structure formation promotion products, and vascularization promotion products.

[0054] As used herein, the terms "a", "an" and "the" include singular and plural references unless the context clearly indicates otherwise. The term "consisting essentially of" is used to define a lipid composition that includes the listed elements but excludes other elements, that is, the term lipid composition is used to define a composition that is essentially composed only of lipids. "Consisting of" thus means excluding elements that exceed trace amounts of other elements. Embodiments defined by each of these transition terms are within the scope of the present invention.

[0055] The present invention provides the aforementioned preparation method, the aforementioned exosome enrichment scaffold, and the use of the aforementioned method for enriching exosomes in a system or device for preparing enriched exosomes.

[0056] The term "system" used in the present invention refers to a system having a structure that connects multiple computers, multiple hardware, devices, etc. to each other via a communication medium such as a network (including communication connections established in a one-to-one manner), or refers to a system implemented by one computer, one hardware, one device, etc. In addition, the term "system" is not limited to multiple components or specific embodiments. For example, a system can be implemented on one or more printed circuit boards or other substrates, and can have movable or static components. Although the following description and examples use the term "system" to describe various aspects of the present invention, the term "system" is not limited to a specific configuration, type or number of objects.

[0057] The present invention provides a system or device for enriching exosomes, wherein the system comprises the aforementioned preparation method and the aforementioned method for enriching exosomes, and the preparation method or method is automatically executed by a computer stored program.

[0058] Furthermore, the computer stored program is automatically executed through an operating device, which includes a memory and a processor.

[0059] Furthermore, a computer program is stored in the memory.

[0060] The term "memory" refers to any type of long-term, short-term, volatile, non-volatile or other memory, and should not be limited to any particular type of memory or any particular number of memories or types of media storing memory. The term "memory" can be any suitable memory element (e.g., random access memory (RAM), read-only memory (ROM), erasable programmable ROM (EPROM), electrically erasable programmable ROM (EEPROM), application specific integrated circuit (ASIC), etc.), software, hardware, firmware, or any other suitable component, device, element or object as appropriate and based on specific needs.

[0061] The term "processor" refers to any type of processor, such as a microprocessor, an embedded processor, a digital signal processor (DSP), a network processor, or other devices for executing code, and may include more than one processor, such as a multi-core design or multiple processors with a multi-core design for each processor. The processor can be configured to execute a sequence of computer program instructions, such as a sequence of those instructions stored in a memory, to perform various operations, processes, and methods according to the exemplary embodiments of the content of the present invention.

[0062] Throughout this specification and the appended claims, unless the context requires otherwise, the word "comprise" and variations such as "comprising" will be understood to imply the inclusion of a stated integer or step or group of integers or steps, but not the exclusion of any other integer or step or group of integers or steps. For example, a composition, mixture, process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process, method, article, apparatus.

[0063] Advantages and beneficial effects of the present invention:

[0064] The present invention establishes a simple and effective method for enriching exosomes using chitosan at different pH values. The developed method allows for the automatic capture and release of exosomes by a bioactive sponge scaffold. In vitro and in vivo studies have shown that exosomes promote regenerative healing by promoting cell proliferation, migration and tubular structure formation, inhibiting inflammation, promoting vascularization and promoting hair follicle regeneration. BRIEF DESCRIPTION OF THE DRAWINGS

[0065] Figure 1is the characterization diagram of T-CS, A is the SEM image of CS at different denaturation temperatures (scale bar = 100 μm); B is the volume change rate of CS, CS-T120, CS-T140, CS-T160, and CS-T180; C is the FTIR spectrum of CS, CS-T120, CS-T140, CS-T160, and CS-T180; D is the adsorption time, all results are shown as mean ± standard deviation, n = 3, **p < 0.01, NS: not statistically significant;

[0066] Figure 2 are characteristic images of exosomes, A is the TEM image of Exo(T-CS), B is the SEM image of exosomes adsorbed by T-CS before and after elution, C is the expression of exosome markers CD81 and CD9 in Exo(UC) and Exo(T-CS), and D is the SEM image of freeze-dried T-CS-E;

[0067] Figure 3 is a graph of exosome diameter (A) and relative efficacy (B);

[0068] Figure 4 Figure 1 is the result of migration and proliferation of exosomes, A is the release characteristic diagram of T-CS scaffold dressing loaded with exosomes; B is the proliferation diagram of HUVECs detected by CCK-8 method; C is the scratch test diagram of HUVECs (scale bar: 400 μm), D is the wound closure analysis diagram, E is the result of tube formation after 6 hours of co-culture (scale bar: 200 μm), and F is the tube formation analysis diagram;

[0069] Figure 5 This is the result graph of the concentration of TNF-α, IL-1β and IL-10 in the cell culture supernatant detected by ELISA;

[0070] Figure 6 is an in vivo wound healing experiment, A is a representative image of the wound surface of each group on days 0, 4, 7, and 14, B is a schematic diagram of the dynamic healing process of the wound, C is a graph showing the change of wound area over time, D is an H&E staining image on days 7 and 14, E is a graph showing the length of the tongue epidermis on day 7, and F is a Masson staining image;

[0071] Figure 7 Figure 1 is the result of immunohistochemistry test. A is the immunohistochemical analysis of TNF-α, IL-1β, and IL-10 in the skin wound of mice on the 7th day after surgery. B is the quantitative expression of TNF-α, IL-1β, and IL-10. C is the protein blot analysis of IL-1β and IL-10 in the skin wound of mice on the 4th day after surgery. Number 1 represents the control group, number 2 represents T-CS-E, and D is the quantitative expression of IL-1β and IL-10.

[0072] Figure 8The figures are the results of Ki67 histochemistry, A is the representative Ki67 immunohistochemistry of wound sections in the treatment group on the 7th day, and B is the analysis of Ki67 positive cells in each treatment group on the 7th day;

[0073] Fig. 9 Figure 1 is a graph showing the results of vascularization detection. A is a representative CD31 immunohistochemistry graph of wound sections on the 7th and 14th days of the treatment group. B is a graph showing the microvessel density analysis of each treatment group on the 7th day. C is a graph showing the microvessel density analysis of each treatment group on the 14th day.

[0074] Fig.10 These are the results of neovascularization on various wound surfaces. A is the immunochemical staining of α-SMA on the wound surface on day 7, and B is the statistical diagram of the number of neovascularization on day 7 in each group.

[0075] Fig.11 These are the results of burn skin healing. A is the skin wound pictures on days 0, 9 and 17, B is the quantitative analysis of the percentage of wound shrinkage area, C is the he staining and Masson trichrome staining of the wound skin tissue on day 17, D is the quantitative analysis of the thickness of granulation tissue and the percentage of collagen area, and E is the wound healing observation picture on day 17. DETAILED DESCRIPTION

[0076] Example 1 Scaffold preparation and exosome separation and enrichment

[0077] 1. Materials and methods

[0078] 1) Preparation of chitosan scaffolds

[0079] Chitosan-sponge composite porous scaffolds were prepared according to the existing method. In short, chitosan (deacetylation degree ≥ 95%, 200-400 mPa; s, Aladdin, China) was dissolved in 1% acetic acid (v / v) and stirred with a magnetic stirrer for 3 hours. Subsequently, the resulting compound was evenly divided into 48-well plates and frozen at -20°C for 3 hours. Chitosan sponge composite porous scaffolds (CS) were obtained by freeze drying at -80°C for 24h. The scaffolds were then thermally modified for 10min-30min at a specific temperature using a constant temperature air drying oven to obtain acid-insoluble scaffolds (T-CS).

[0080] 2) Cell culture and exosome isolation

[0081] Human umbilical cord mesenchymal stem cells (hUC-MSCs) were isolated from fresh human umbilical cord by digestion and centrifugation, cultured in α-MEM medium containing 10% FBS and 1% penicillin-streptomycin solution (Gibco, USA) as described above, and used for experiments before passage 6 times. HUVEC cell line (c-12,206, Promo cell, Germany) was cultured in DMEM medium containing 10% FBS and 1% penicillin-streptomycin solution (Gibco, USA). Both cells were tested for bacterial, fungal, mycoplasma and viral contamination and found to be free of these contaminants.

[0082] Exosomes were isolated by conventional ultracentrifugation (UC)

[26] and modified scaffold separation methods. hUC-MSCs were cultured in exosome-free medium at 37°C for 48 h, and the culture medium (CCM) was collected and centrifuged at 300×g for 10 min at room temperature to separate cells and obtain exosomes. The UC method pelleted dead cells at 2000×g for 10 min at 4°C, and exosomes were pelleted at 16500×g for 20 min, followed by ultracentrifugation at 100,000×g (WX100+, Thermo Fisher Scientific, USA) for 70 min. After discarding the supernatant, the exosome pellet was washed with PBS, ultracentrifuged at 100,000×g for 70 min, and all the liquid was removed. Finally, the exosomes were resuspended in 200μL 1× PBS. To adsorb exosomes on T-CS, CCM was filtered through a 0.2 μm diameter filter to remove dead cells and cell debris, then mixed with MES buffer (pH = 6.0) at a ratio of 1:4, and the pH value was adjusted to 5.8-6.2, and then T-CS scaffolds were added to the mixture and shaken on ice for 30 min. T-CS bound to exosomes was directly used for animal experiments, analysis, freeze-dried, or collected after washing with NaHCO3 (pH = 8.0-10.6) to release exosomes.

[0083] 3) Characteristics of T-CS and exosomes

[0084] The morphology of T-CS and its bound exosomes was observed using a 5.0 kV scanning electron microscope (ZEISS Gemini SEM 300). To obtain the conductivity, a thick layer of gold metal was applied. Nicolet iS20 spectrophotometer (ThermoScientific, USA) was used at 400–4000 cm -1 Fourier transform infrared spectroscopy (FTIR) was used to analyze the structures of CS and T-CS.

[0085] The volume of the CS or T-CS scaffold (V1) was measured and then immersed in MES buffer (pH = 6.0) for about 2 h until saturated. The saturated scaffold was measured and marked as V0. The scaffold volume change rate was calculated as follows:

[0086] Volume change rate = (V0-V1) / V1×100%

[0087] The protein content in the exosome suspension was determined using the Bicinchoninic Acid (BCA) microquantification kit from Beyotime (Shanghai, China). The protein content in the exosome suspension was determined using a conventional transmission electron microscope (TEM) from Hitachi HT-7700 and a Particle Metrix equipped with a 520 nm laser. Nanoparticle tracking analyzer (NTA) and Western blot were used to analyze the morphology, size, and expression of markers CD9 and CD81 of hUC-MSC-derived exosomes. Primary antibodies against CD9 (ab223052) and CD81 (ab155760) were purchased from Abcam. Exosomes were stored at -80°C or used in experiments.

[0088] 2. Experimental results

[0089] 1) Preparation and characterization of T-CS

[0090] The chitosan scaffolds were denatured at different temperatures (120℃, 140℃, 160℃, 180℃). They were identified as CS-T120, CS-T140, CS-T160, and CS-T180. The porous morphology of the scaffolds was observed by scanning electron microscopy (SEM); as the denaturation temperature increased, the porous layered structure gradually merged inside the scaffold. At 160℃ and 180℃, the pores of the scaffolds tended to become larger, but they remained porous. The results are shown in Figure 2. Figure 1 As shown. The expansion of the scaffold in an acidic environment determines its structural stability and suitability for wound healing dressings. Therefore, the expansion of each scaffold in MES buffer at pH 6.0 was tested. Figure 1 As shown in Figure B, the untreated CS had the highest swelling rate in acidic solution, which was about 66.5% of the original size. The swelling rate of CS-T120 was about 40%, while the minimum swelling rate of CS-T160 and CS-T180 was about 20%. In addition, the untreated CS recovered to a gel state before freeze-drying in MES buffer at pH 6.0. In contrast, CS-T160 and CS-T180 remained porous sponges in an acidic environment for more than 14 days. Therefore, after thermal deformation, CS-T160 and CS-T180 maintained porous morphology in an acidic environment and enhanced mechanical properties, making them ideal biomaterials for skin repair.

[0091] The peak characteristics of -NH2 were successfully retained by FTIR detector analysis of CS, CS-T120, CS-T140, CS-T160 and CS-T180. In the FTIR spectra of all samples, the peaks of -NH2 were 3500-3100 cm -1 and 1640~1550cm -1 The broad peaks observed at are caused by NH and OH stretching, indicating that these scaffolds carry positive charges. Since the phosphate groups of the exosome phospholipid bilayer membrane are negatively charged, chitosan with positively charged groups can effectively capture exosomes, nucleic acids, proteins, and bioactive substances by electrostatic adsorption in acidic solutions.

[0092] The ability of T-CS to capture exosomes at different time points was indirectly reflected by measuring protein concentration. Figure 1 As shown in D, the protein concentration was about 1000 μg / ml at 30 min, and there was no significant difference between the protein concentration at 60 min and that at 30 min, indicating that the exosome adsorption limit had been reached at 30 min. The results showed that high temperature treatment at 160-180 °C could improve the insolubility of chitosan scaffolds and their low expansion rate in acidic solutions. Therefore, a T-CS porous sponge scaffold that can capture exosomes in an acidic environment was successfully constructed.

[0093] 2) Preparation and characterization of exosomes isolated from T-CS

[0094] The exosomes adsorbed by T-CS were analyzed and identified, and the transmission electron microscopy (TEM) images showed the morphology of Exo(T-CS), which had a "disc-like" exosome structure ( Figure 2 A). Figure 2 B shows the SEM images of T-CS before (left panel) and after (right panel) elution with 0.1 mM NaHCO3 solution (arrows indicate exosomes). The particle size of the exosomes obtained from Exo(UC) and Exo(T-CS) was analyzed by NTA. The average particle sizes of Exo(UC) and Exo(T-CS) were (141.2±54nm) and (131.7±56nm), respectively. The diameters of the exosomes obtained by the two methods were relatively similar. Then, the protein concentration of the exosomes extracted by the two methods was detected by the microbial bicinchoninic acid (BCA) protein detection kit to evaluate the exosome extraction efficiency of the two methods. The exosome yield adsorbed by T-CS was about 1.5 times that of UC. The exosomes derived from hUC-MSC have specific surface protein markers CD9 and CD81, which can be recognized by specific antibodies. Western Blot was used to detect protein markers of T-CS and UC exosomes. The main proteins including CD9 and CD81 were present in both Exo(T-CS) and Exo(UC). Figure 2C). Storage of extracellular vesicles at room temperature is a barrier to exosome applications, as shown in SEM imaging ( Figure 2 D) After lyophilization of exosomes combined with T-CS, they can be conveniently transported and stored at room temperature without compromising the molecular integrity of the exosomes.

[0095] Currently, the most commonly used method for isolating exosomes is differential centrifugation, followed by ultracentrifugation. However, this method is considered time-consuming and inefficient. Given the wide range of biological effects of exosomes, it is crucial to develop high-yield, high-quality separation methods. The results showed that T-CS was able to adsorb and release MSC-derived exosomes. Centrifugation is conducive to the separation of large-size particles, while electrostatic adsorption is more suitable for small-size particles. Due to the different principles of electrostatic adsorption and centrifugal adsorption, the volume of exosomes adsorbed by T-CS is slightly smaller than that of exosomes separated by UC. After elution with NaHCO3 solution, a small amount of exosomes was observed on the surface of T-CS, confirming its ability to effectively release exosomes ( Figure 3 ). The freeze-dried scaffold (FT-CS-E) showed that the exosomes adsorbed by T-CS could be firmly attached to the surface of T-CS, which was beneficial for preservation and transportation. Since the adsorption of exosomes on T-CS depends on electrostatic interactions, T-CS can have a capture effect on all negatively charged extracellular vesicles (including EVs, sEVs, apoptotic bodies, etc.). In addition, compared with the exosomes obtained by UC, the exosomes adsorbed by T-CS had similar disc-like shapes, protein surface markers, slightly smaller average diameters, and higher protein acquisition rates.

[0096] Example 2 Functional Verification

[0097] 1. Experimental methods

[0098] 1) Exosome release analysis

[0099] According to previous studies, the exosome release from T-CS scaffolds was evaluated using the BCA protein detection kit. At predetermined time points, 100 μg of exosome solution (approximately 100 μl) was added to the T-CS scaffolds, shaken vigorously at 4°C, and then incubated at 37°C for 1 h. Next, the T-CS scaffolds (containing 100 μg of exosomes) and PBS (pH = 7.4) were added to the upper and lower chambers of the Transwell insert in a 24-well plate, respectively. The exosome release from the T-CS scaffolds was detected by the BCA method. At specific time points (days 3, 6, 9, 12, 15, 18, and 21), PBS was collected from the lower chamber and replaced with fresh PBS. The exosomes released from the scaffolds were measured, and the release curve was calculated, expressed as the percentage of release over time.

[0100] 2) Cell proliferation, migration, tubule formation and inflammation experiments

[0101] In the proliferation experiment, the Transwell system (Corning 8μm) was used to detect the effect of T-CS-derived exosomes on HUVEC proliferation; the culture wells were divided into 3 groups for analysis: 1) Exo(UC) group: 100μg / ml hUC-MSC-derived exosomes; 2) Exo(T-CS) group: T-CS-E released hUC-MSC-derived exosomes 100μg / ml; 3) PBS group: 1% PBS. HUVECs were placed in the lower chamber of the Transwell system, and 3 intervention substances were added to the upper chamber. On days 1, 2, 3, 4, and 5 after inoculation, CCK-8 reagent was added to the culture medium, and the results were analyzed after incubation at 37°C for 1h.

[0102] Cell migration was assessed by scratch assay, 1.2 × 10 5 HUVECs cells were seeded in 6-well plates and cultured to 100% confluence. They were divided into 3 groups: 1) Exo(UC) group: 100μg / ml hUC-MSC-derived exosomes; 2) Exo(T-CS) group: 100μg / ml hUC-MSC-derived exosomes released by T-CS-E; 3) PBS group: 1% PBS. Three parallel scratches were made in each well with a modified yellow pipette tip, and then washed three times with PBS. The width of each scratch was measured as the baseline value. The cells were placed in a 5% CO2 incubator and cultured for 0h, 12h, and 24h. ImageJ software was used to simulate the scratch experiment and visualize the scratch width.

[0103] Tube formation was measured using the Matrigel method. 250 μl of reduced growth factor Matrigel (Corning, USA) was added to each well of a 24-well plate and placed in a cell culture incubator for 30 min to allow the gel to solidify. HUVECs were first co-cultured with exosomes (from UC or T-CS-E) or PBS for 48 h, and then approximately 300 μl of conditioned medium containing 75,000 resuspended HUVECs was inoculated in the pre-coated wells and cultured for 6 h. The formed tubes were observed under an optical microscope, and the number of tubes was counted and calculated according to the manufacturer's instructions.

[0104] Enzyme-linked immunosorbent assay (ELISA) was used to detect the levels of inflammatory and anti-inflammatory factors. RAW264.7 cells were cultured in 24-well plates and treated with PBS, LPS, LPS+Exo (UC), and LPS+Exo (T-CS) for 24 h. The resulting supernatants were collected and analyzed for the levels of IL-1β, TNF-α, and IL-10 using IL-1β ELISA kits, TNF-α ELISA kits, and IL-10 ELISA kits, respectively. The manufacturers were from Neobioscience, quantiyto.

[0105] 3) In vivo experiments

[0106] All experimental animals were approved by the Institutional Animal Care and Use Committee (IACUC) of PLA General Hospital and were conducted in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Male C57BL / c mice weighing 18-22 g (Vital River, China) were selected. The back hair was shaved under general anesthesia, and the back hair was removed with a depilatory cream. A full-thickness wound was made on the back skin with a 7-mm diameter dermal biopsy punch. The mice were divided into five groups: control group (wound covered with sterile gauze only), T-CS group (wound covered with T-CS scaffold and sterile gauze), T-CS-E group (wound covered with T-CS self-loaded exosomes), T-CS+Exo group (T-CS scaffold containing 100 μg exosomes isolated from UC), and FT-CS-E group (freeze-dried T-CS-E scaffold stored at room temperature for more than 30 days). All mice were housed in a room with a 12-h light / dark cycle and stable temperature and humidity (25°C). On the 4th, 7th, and 14th days after surgery, mice in each group were photographed and killed by injection of a lethal dose of sodium pentobarbital to evaluate skin repair. For the skin burn model, after anesthesia and disinfection of the back with iodine, a solid aluminum rod with a diameter of 10 mm and a weight of 51 g was placed on the back of the mouse for 15 seconds, and the aluminum rod was placed in boiling water and heated to 100°C for 10 minutes. Wound photos were taken on the 0th, 9th, and 17th days after surgery, and mice were killed on the 17th day after surgery according to the wound healing status.

[0107] 4) Histological analysis

[0108] Healed skin tissue samples were fixed with 10% formalin, dehydrated with alcohol, and embedded in paraffin. Sections with a thickness of 5 μm were subjected to hematoxylin-eosin (H&E) staining, Masson trichrome staining, and immunohistochemical staining. After dewaxing and inactivation of endogenous peroxidase, sections were antigen retrieved, blocked, and incubated with antibodies against CD31 (ab181595, Abcam, Cambridge, UK) α-SMA (BM0002), Ki67 (ab15580, Abcam, Cambridge, UK), IL-1β (26048-1-AP), TNF-α (17590-1-AP), and IL-10 (60269-1-Ig) overnight at 4°C. Secondary antibodies were then applied at 37°C for 30 min, followed by reaction with diaminobenzidine (DAB) and counterstaining with hematoxylin. Image ProPlus software was used to quantify the expression of CD31 and calculate the vascular density.

[0109] 5) Western Blot analysis of inflammatory factors

[0110] The tissues collected on the 4th day after injury were quickly immersed in liquid nitrogen and then frozen at -80°C until homogenized. Homogenization was achieved by adding protease inhibitor cocktail to RIPA protein lysis buffer, and then the tissue samples (100 mg) were homogenized using an IKA T10 basicULTRA-TURRAX (Germany) homogenizer. The samples were then sonicated for 1 minute and centrifuged at 5,000 rpm for 10 minutes at 4°C. The protein concentration was detected by the BCA method. Equal amounts of protein samples (50 μg) were loaded on SDS-PAGE gels and separated, and then transferred to polyvinylidene fluoride (PVDF) membranes with a pore size of 0.22 μm. The membrane was blocked with 5% skim milk and incubated overnight with specific antibodies (including IL-1β (1:2000), IL-10 (1:2000) and GAPDH (1:2000)) (all from Proteintech). The next day, incubated with horseradish peroxidase (HRP)-labeled secondary antibodies for 2 hours at room temperature. Image-J software was used to quantitatively analyze the expression intensity of IL-1β, IL-10 and GAPDH.

[0111] 6) Statistical analysis

[0112] All experimental data were analyzed using IBM SPSS Statistics 27 and GraphPad Prism 7. Independent sample T test was used for comparison between two groups, and one-way analysis of variance was used for comparison between multiple groups. All data are expressed as mean ± standard deviation (mean ± SD). p < 0.05 was considered statistically significant.

[0113] 2. Experimental results

[0114] 1) Release of T-CS exosomes promotes migration and proliferation

[0115] The BCA protein detection kit was used to detect the exosomes released from the T-CS-E scaffold in alkaline solution. Figure 4 As shown in A, the release time in pH = 7.4 solution is more than 21 days. The change of pH value allows the controlled release of exosomes in alkaline solution for subsequent particle size analysis or other purposes. Therefore, the T-CS scaffold loaded with exosomes shows a sustained release effect on exosomes in an alkaline environment. Exosomes are phospholipid bilayer structures with negatively charged phosphate groups. Exosomes can be captured and released by changing the surface charge polarity of chitosan. Using the pH in the environment to adjust the charge polarity of chitosan seems to be an extremely simple and feasible operation method.

[0116] The biological effect of exosomes released from the T-CS scaffold was further verified in an in vitro study of endothelial cells. CCK-8 experiments showed that on the 4th and 5th days, the proliferation of endothelial cells in the Exo(T-CS) and Exo(UC) treatment groups was better than that in the control group, and there was no statistical difference between the Exo(T-CS) and Exo(UC) treatment groups, indicating that the exosomes isolated from T-CS and UC maintained the biological activity of promoting cell proliferation ( Figure 4 B). In addition, the results of cell migration experiments also confirmed that Exo(T-CS) can significantly enhance the migration ability of endothelial cells. Figure 4 As shown in C-4D, the Exo(UC) and Exo(T-CS)-treated groups exhibited greater cell migration at 24 h, and the migration ability of endothelial cells in the Exo(UC) and Exo(T-CS)-treated groups was similar.

[0117] Inflammation is a key factor leading to chronic and refractory wound healing, so anti-inflammatory drugs play a key role in promoting wound healing. A large number of studies have shown that exosomes derived from mesenchymal stem cells have significant anti-inflammatory effects in the process of wound repair. The anti-inflammatory properties of exosomes obtained by adsorption were evaluated, in which the pro-inflammatory M1 phenotype was induced to the anti-inflammatory M2 phenotype. Figure 5 It can be seen that both the exosomes obtained by T-CS adsorption and the exosomes isolated by UC significantly inhibited the levels of TNF-α and IL-1β induced by LPS, while also promoting the levels of IL-10. There was no statistically significant difference between the two types of exosomes. Based on these findings, we believe that the exosomes adsorbed by T-CS have similar anti-inflammatory effects as those obtained by UC.

[0118] 2) In vivo wound healing

[0119] Figure 6 A shows representative wound area images of each group at 0, 4, 7, and 14 days after surgery. On day 4, there was no significant difference in wound healing among the groups. However, on days 7 and 14, the wound closure rates of the T-CS+Exo, T-CS-E, and FT-CS-E treated groups were faster than those of the control and T-CS treated groups ( Figure 6 C). On the 7th day, the wound surface of the T-CS+Exo group, T-CS-E group, and FT-CS-E group had more granulation tissue and a longer epidermal tongue ( Figure 6 D). On the 14th day, new hair follicles were observed in the wound center of each group, the epidermis was completely closed and tightly connected to the dermis, and the collagen in the new dermis was arranged in an orderly manner. On the 7th day, compared with the control group and the T-CS group, the length of the epidermal tongue in the T-CS+Exo group, the T-CS-E group, and the FT-CS-E group was significantly longer ( Figure 6 E). Figure 6F shows the deposition of new collagen in the wound under different treatments. Masson trichrome staining showed that compared with the control group and T-CS group, the collagen fiber breakage in the T-CS-E group, T-CS+Exo group, and FT-CS-E group was significantly reduced.

[0120] The exosome adsorption scaffold based on thermally modified chitosan uses the charge difference of exosomes under different pH environments to capture and release exosomes, thereby achieving controllable exosome release. The results showed that T-CS-E continuously released exosomes for more than 21 days, which could overcome the rapid clearance of exosomes and ensure their participation in the entire repair process of the wound surface. In addition, T-CS-E can be stored for a long time at room temperature after freeze-drying, further demonstrating the excellent performance of the composite scaffold.

[0121] 3) Anti-inflammatory effect of T-CS-E in vivo

[0122] Inflammatory response hinders the wound healing process, and stem cell-derived exosomes have anti-inflammatory properties. On the 7th day after surgery, we used immunohistochemistry to detect the expression of two pro-inflammatory factors (TNF-α, IL-1β) and one anti-inflammatory factor (IL-10) in the new tissues of different treatment groups. Compared with the control group, the expression levels of TNF-α in the T-CS+Exo group, T-CS-E group, and FT-CS-E group were 0.55±0.01, 0.56±0.01, and 0.58±0.11, respectively. The relative expression levels of IL-1β were 0.78±0.08, 0.73±0.08, and 0.87±0.03, respectively. The expression of IL-10 was 2.8±0.31, 2.88±0.29, and 2.6±0.29 times that of the control group, respectively. Figure 7 ). Therefore, we believe that on the 7th day after surgery, T-CS-E promotes the expression of IL-10 by inhibiting TNF-α and IL-1β, thereby playing a pro-healing role.

[0123] On postoperative day 4, we further performed Western Blot analysis on wound samples to evaluate the status of IL-1β and IL-10. Figure 7 The results showed that the expression of pro-inflammatory factor IL-1β in the T-CS-E group was reduced by 0.73±0.16 times compared with the control group (p=0.047), while the expression of IL-10 was increased by 1.5±0.31 times compared with the control group (p=0.045). Therefore, T-CS-E seems to exert its anti-inflammatory effect by promoting the expression of IL-10 and inhibiting the expression of IL-1β, both of which are key to the anti-inflammatory effect of exosomes.

[0124] 4) T-CS-E promotes cell proliferation and angiogenesis in vivo

[0125] The cell proliferation marker Ki67 was detected in the wound specimens on the 7th day after surgery. Figure 8As shown. Among the groups, the number of Ki67-positive cells in the T-CS-E group was the highest, followed by the T-CS+Exo group and the FT-CS-E group, which were significantly higher than those in the T-CS group and the control group. The large-scale cell proliferation in the wound surface indirectly reflects the rapid formation of granulation tissue in the wound surface after exosome treatment.

[0126] The process of new blood vessel formation, called angiogenesis, is essential for wound healing as it provides oxygen and nutrients to the healing cells and supports the newly formed granulation tissue. CD31 is an endothelial cell marker that can be used to determine the degree of tissue vascularization. Fig. 9 It can be clearly seen that after 7d and 14d of treatment, the number of blood vessels in the T-CS+Exo group, T-CS-E group and FT-CS-E group was significantly higher than that in the T-CS group and the control group. On the 7th day, the MVD density in the T-CS+Exo group, T-CS-E group and FT-CS-E group was significantly higher than that in the other groups.

[0127] Immunofluorescence staining of α-smooth muscle actin (α-SMA) in wound samples was performed on day 7 to investigate the activation of angiogenic response in vivo. Fig.10 As shown, there was little α-SMA positive staining in the control group and T-CS group, while the α-SMA positive expression was strongest in the T-CS+Exo group, T-CS-E group, and FT-CS-E group. The number of newly formed blood vessels was also quantified, and the number of blood vessels per field in the wounds treated with T-CS+Exo, T-CS-E, and FT-CS-E scaffolds was >40, which was significantly more than the number of blood vessels per field in the wounds treated with PBS and T-CS scaffolds, which was <20. These results indicate that T-CS+Exo, T-CS-E, and FT-CS-E scaffold dressings can effectively activate the angiogenesis process during wound healing.

[0128] 5) T-CS-E can accelerate the healing of burn skin injury wounds in vivo

[0129] Given the potent anti-inflammatory properties of T-CS-E, we also investigated its effects on the healing of burn skin injuries, which are characterized by severe inflammation. A mouse skin burn model was established, and representative photos of skin wounds at different time points are shown in Fig.11 We observed that after 9 days, the healing rates were fastest in the T-CS+Exo, T-CS-E, and FT-CS-E groups, and the wounds in these groups were almost completely closed by day 17. Therefore, we sacrificed all mice on day 17 after surgery.

[0130] The morphology of burn wounds was evaluated by H&E staining. The wounds of mice in the T-CS+Exo, T-CS-E, and FT-CS-E groups were completely healed, and the epidermal tissue was thicker. The wounds in the control and T-CS groups healed poorly, and the epidermis was relatively thin. It is worth noting that the burn wounds were completely covered by a layer of epidermis, and the thickness of granulation tissue in the T-CS+Exo, T-CS-E, and FT-CS-E groups was higher than that in the control and T-CS groups. We also performed Masson staining, and the results showed that the collagen deposition in the T-CS+Exo, T-CS-E, and FT-CS-E groups was more obvious than that in the control and T-CS groups. These results indicate that the effective effects of the T-CS+Exo, T-CS-E, and FT-CS-E groups on the healing of burn skin wounds are due to their ability to effectively promote the secretion and deposition of collagen fibers in the skin.

[0131] The description of the above embodiments is only used to understand the method and core idea of ​​the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.

Claims

1. A method for preparing an exosome-enriched scaffold, characterized in that: The preparation method comprises the following steps: 1) Dissolve chitosan in 1% v / v acetic acid, mix well to make it fully dissolved, and the final concentration of chitosan is 1%-3%; 2) Freezing at -20°C for 3 hours, and freeze-drying at -80°C for 24 hours to obtain a chitosan-sponge composite porous scaffold; 3) The chitosan-sponge composite porous scaffold is subjected to constant temperature drying and heat modification for 10 min to 30 min, wherein the constant temperature is 160° C. to 180° C., to obtain the final product, an acid-insoluble scaffold.

2. The preparation method according to claim 1, wherein the mixing in step 1) includes stirring mixing and shaking mixing, and the mixing time is 3 hours.

3. The preparation method according to claim 1, wherein the drying in step 3) comprises forced air drying.

4. The preparation method according to claim 1, wherein the exosomes comprise stem cell exosomes. The preparation method according to claim 1 , wherein the exosomes comprise mesenchymal stem cell exosomes.

6. The preparation method according to claim 1, wherein the exosomes include exosomes produced by bacteria.

7. The preparation method according to claim 1, wherein the exosomes comprise somatic cell exosomes.

8. An exosome-enriched scaffold prepared according to the preparation method according to any one of claims 1 to 7.

9. A method for enriching exosomes, characterized in that: The method comprises the following steps: 1) mixing the exosome solution with the MES buffer at a ratio of 1:4, adjusting the pH value, and then adding the exosome enrichment scaffold described in claim 8, mixing on ice, and obtaining exosomes bound to the exosome enrichment scaffold; 2) washing with an alkaline solution to release the exosomes on the exosome enrichment scaffold to obtain an exosome enrichment product.

10. The method according to claim 9, wherein the pH value is comprised between 5.8 and 6.

2. The method according to claim 9 , wherein the concentration of the MES buffer is 100 mM.

12. The method according to claim 9, wherein the mixing time on ice is 30 min and the mixing method is oscillation mixing.

13. The method according to claim 9, wherein the alkaline solution comprises a solution prepared from sodium phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium phosphate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, ammonium phosphate, ammonium dihydrogen phosphate, and / or diammonium hydrogen phosphate.

14. The method according to claim 9, wherein the alkaline solution is a NaHCO3 solution.

15. The method according to claim 14, wherein the pH value of the NaHCO3 solution is 8.0-10.

6.

16. The method according to claim 14, wherein the concentration of the NaHCO3 solution is 10 mM.

17. The method according to claim 9, wherein the exosome solution further comprises a preliminary impurity removal step.

18. The method according to claim 17, wherein the step of preliminary impurity removal comprises: The exosome solution was filtered to remove dead cells and cell debris.

19. The method according to claim 9, wherein the steps of the method for enriching exosomes can be repeated continuously.

20. A method for storing and transporting exosomes, characterized in that: The method comprises freeze-drying the exosomes bound to the exosome enrichment scaffold in step 1) of any one of claims 9 to 19 as a whole, and then directly transporting and / or storing at room temperature.

21. The method according to claim 20, wherein the molecular integrity of the lyophilized exosomes is not compromised when transported and / or stored at room temperature.

22. A composition prepared by the method according to any one of claims 9 to 19, characterized in that: The composition includes exosomes bound to an exosome-enriched scaffold, and / or collected exosomes.

23. Use of the preparation method according to any one of claims 1 to 7 in preparing an exosome-enriched scaffold.

24. Use of the preparation method according to any one of claims 1 to 7, the exosome-enriched scaffold according to claim 8, the method according to any one of claims 9 to 19, or the composition according to claim 22 in preparing a product.

25. The use according to claim 24, wherein the products include wound repair products, brain injury treatment products, tissue regeneration products, tissue reconstruction products, inflammation suppression products, immunomodulatory products, paracrine regulation products, hair follicle regeneration products, cell proliferation promotion products, cell migration promotion products, cell tubular structure formation promotion products, and vascularization promotion products.

26. Use of the preparation method according to any one of claims 1 to 7, the exosome enrichment scaffold according to claim 8, or the method according to any one of claims 9 to 19 in a system or device for preparing enriched exosomes.

27. A system or device for enriching exosomes, characterized in that: The system comprises the preparation method according to any one of claims 1 to 7 and the method according to any one of claims 9 to 19, and the preparation method or the method is automatically executed by a computer stored program.